HIGHOutside partySupplier
Fresenius Kabi
“10-K Item 1: 'we rely solely on Fresenius Kabi AG, or Fresenius, for the manufacture of disposable kits for the platelet and plasma systems.'”
CERS · Concentration risk · 10-K extracted
Cerus (CERS) concentration risks
Updated
The most significant concentration Cerus discloses is Fresenius Kabi, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Cerus’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH3
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partyCustomer
American Red Cross
“10-K Item 1A: 'Our ability to achieve and maintain significant market penetration in the U.S. is largely dependent on utilization of INTERCEPT and distribution of INTERCEPT-treated blood components by the American Red Cross.'”
HIGHBuilt-inProduct / Revenue mix
INTERCEPT Blood System (platelets, plasma, cryoprecipitation)
“10-K Item 1A: 'We depend substantially upon the commercial success of the INTERCEPT Blood System for platelets, plasma and cryoprecipitation in the U.S.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Cerus Corporation carries concentration risk on three fronts that reinforce rather than offset one another. On the supply side, the company relies solely on Fresenius Kabi AG for manufacture of the disposable kits used in its platelet and plasma systems, a high-level single-source dependency with no disclosed alternative manufacturer. On the demand side, achieving and maintaining meaningful U.S. market penetration is described as largely dependent on the American Red Cross's utilization and distribution of INTERCEPT-treated blood components, another high-level dependency on a single counterparty. Underlying both is a product concentration: commercial success is substantially tied to the INTERCEPT Blood System for platelets, plasma, and cryoprecipitation in the U.S., also disclosed at a high level. None of the three is merely idiosyncratic — together they describe a single-product company whose manufacturing and U.S. distribution each run through one counterparty, so a disruption at either Fresenius Kabi or the American Red Cross would have an outsized effect on the entire business rather than one segment of it.
For the engine’s reasoning on CERS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| CERS● | Cerus Corporation | 3 | 0 | 0 | 3 |
| AVNS | Avanos Medical, Inc. | 2 | 0 | 1 | 3 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| AHCO | AdaptHealth Corp. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.